Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: A multicenter phase II study

Peter Mu Hsin Chang, Cheng Hwai Tzeng, Ming Huang Chen, Chao Jung Tsao, Wu Chou Su, Wei Shuo Hwang, Yi Fang Chang, Shyue Yih Chang, Muh Hwa Yang

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Purpose: To test the efficacy and safety of a triweekly reduced-dose docetaxel (60 mg/m 2) regimen combined with a standard dose of cisplatin in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Patients and methods: Patients with R/M HNSCC were enrolled. All eligible patients received intravenous docetaxel 60 mg/m 2 combined with cisplatin 75 mg/m 2 on day 1 and then every 3 weeks thereafter. Treatment was continued until disease progression, patient intolerance, or death. Results: In total, 58 patients were enrolled and 41 patients were evaluated. Among the evaluated population, one patient achieved a complete response (2.4%) and nine patients achieved a partial response (22%), resulting in an overall response rate of 24.4%. Furthermore, 17 patients had stable disease (41.5%), which corresponds to a disease control rate of 65.9%. With a median follow-up of 24 months (1-43 months), progression-free survival was 170 days (95% confidence interval 97.9-242.1) and the median overall survival was 265 days (95% confidence interval 89.0-441.0) in evaluable population. The most common toxicities (≥grade III) were leucopenia (66.7%) and anemia (33.3%). Conclusions: Triweekly reduced-dose docetaxel 60 mg/m 2 combined with cisplatin is effective and feasible for Taiwanese patients with R/M HNSCC. However, the hematologic toxicity of this regimen should be carefully monitored and managed.

Original languageEnglish
Pages (from-to)1477-1484
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume68
Issue number6
DOIs
Publication statusPublished - 2011 Dec

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: A multicenter phase II study'. Together they form a unique fingerprint.

Cite this